Annalise Mathers

Ms. Annalise Mathers

University of Toronto
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2018 in Journal of Medical Internet Research
Verified
Journal Article
Open access
KLKarla Lancaster
Karla Lancaster
AAAseel S Abuzour
Aseel S Abuzour
Manmeet KhairaManmeet Khaira
Manmeet Khaira
AMAnnalise Mathers
Annalise Mathers
ACApril Chan
April Chan
LDLisa Dolovich
Lisa Dolovich
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: eHealth tools are becoming increasingly popular for helping patients self-manage chronic conditions. Little research has examined the effect of ehealth tools for patient self-reporting on medication management. This review aims to determine whether ehealth tools featuring patient self-reporting of symptoms, adverse effects and drug therapy problems are effective at prompting medication changes and improving patient outcomes. Objective: The primary objective is to determine how patient self-reporting of symptoms and adverse effects via ehealth tools influences medication use and changes made to medications. Secondary objectives are to investigate how patient use of ehealth tools influences identification of adverse events, patient self-management of disease and self-efficacy, medication use behaviour, medication reconciliation and recommendations for drug changes, changes in patient signs and symptoms, health services utilization, quality of life, and patient satisfaction with health care. Methods: MEDLINE, EMBASE and CINAHL were searched from Jan 1, 2000 through to January 4, 2016. References were also searched. Title, abstract and full text review, as well as data abstraction and risk of bias assessment were performed in duplicate. Due to high heterogeneity, results were not meta-analyzed, and instead presented as a narrative synthesis. Results: 13 studies, including 10 randomized controlled trials (RCTs) and 3 single-arm cohort studies were included, from which 10 unique ehealth tools were identified. Here six of seven RCTs found improvement in patient symptoms following ehealth tool use, especially in adolescent asthma patients. Four of six RCTs reported that ehealth tools may have potential to initiate changes to medications based on patient self-reports. Two of four RCTs showed that ehealth tools may improve patient self-efficacy and self-management of chronic disease. Little or no evidence was found to support the effectiveness of ehealth tools at improving medication recommendations and reconciliation by clinicians, medication-use behaviour, health service utilization, quality of life, or patient satisfaction. eHealth tools with multifaceted functionalities and those allowing direct patient-provider communication may be more effective at improving patient self-management and self-efficacy. Conclusions: Initial evidence showing ehealth tools may improve patient symptoms and lead to medication changes is promising. Patients generally found ehealth tools useful in improving communication with health care providers. Implementation issues such as poor patient engagement and poor clinician workflow integration were identified. More high-quality research is needed to explore how ehealth tools can be used to effectively manage use of medications to improve patient outcomes.

1 November 2016 in Social Science & Medicine
Verified
Journal Article
Closed access
JSJeremy Snyder
Jeremy Snyder
AMAnnalise Mathers
Annalise Mathers
VCValorie A. Crooks
Valorie A. Crooks

30 January 2017 in Journal of Medical Ethics
Verified
Journal Article
Open access
PDF file
JSJeremy Snyder
Jeremy Snyder
VCValorie A Crooks
Valorie A Crooks
AMAnnalise Mathers
Annalise Mathers
PCPeter Chow-White
Peter Chow-White
Medical crowdfunding is growing in terms of the number of active campaigns, amount of funding raised and public visibility. Little is known about how campaigners appeal to potential donors outside of anecdotal evidence collected in news reports on specific medical crowdfunding campaigns. This paper offers a first step towards addressing this knowledge gap by examining medical crowdfunding campaigns for Canadian recipients. Using 80 medical crowdfunding campaigns for Canadian recipients, we analyse how Canadians justify to others that they ought to contribute to funding their health needs. We find the justifications campaigners tend to fall into three themes: personal connections, depth of need and giving back. We further discuss how these appeals can understood in terms of ethical justifications for giving and how these justifications should be assessed in light of the academic literature on ethical concerns raised by medical crowdfunding.

7 December 2020 in Pharmacy
Verified
Journal Article
Open access
PDF file
Manmeet KhairaManmeet Khaira
Manmeet Khaira
AMAnnalise Mathers
Annalise Mathers
NGNichelle Benny Gerard
Nichelle Benny Gerard
LDLisa Dolovich
Lisa Dolovich
The movement to integrate pharmacists into a primary care team-based settings is growing in countries such as Canada, the United States, the United Kingdom, and Australia. In the province of Ontario in Canada, almost 200 pharmacists have positions within interdisciplinary primary care team settings, including Family Health Teams and Community Health Centers. This article provides a narrative review of the evolving roles of pharmacists working in primary care teams, with a focus on evidence from Ontario, as well as drawing from other jurisdictions around the world. Pharmacists within primary care teams are uniquely positioned to facilitate the expansion of the pharmacist’s scope of practice, through a collaborative care model that leverages, integrates, and transforms the medication expertise of pharmacists into a reliable asset and resource for physicians, as well as improves the health outcomes for patients and optimizes healthcare utilization.

3 May 2018 in Tobacco Control
Verified
Journal Article
Closed access
PDF file
AMAnnalise Mathers
Annalise Mathers
RSRobert Schwartz
Robert Schwartz
SOShawn O’cOnnor
Shawn O’cOnnor
MFMichael Fung
Michael Fung
LDLori Diemert
Lori Diemert
Introduction Phillip Morris International (PMI) is pushing hard to promote IQOS heat-not-burn cigarettes in Ontario, Canada. Canada regulates IQOS as a tobacco product so that the robust tobacco marketing ban creates challenges to its promotion. Methods We collected data on IQOS promotion in 49 retail outlets, and through interviews with clerks and observations outside an IQOS store. Results The dominant marketing channel is the visible availability of IQOS in a large number of tobacco retail outlets—1029 across Ontario. Several stores display the price of ‘heated tobacco’ on one of three price signs which are permitted despite Ontario’s total display ban. IQOS boutique stores are the locus of aggressive promotion including exchanging a pack of cigarettes or lighter for an IQOS device, launch parties, ‘meet and greet’ lunches and after-hour events. Outside the store, promotion includes a prominent IQOS sign, a sandwich board sign reading ‘Building a Smoke-Free Future’ and sales representatives regularly smoking IQOS. Membership services: Upon acquiring an IQOS device one can register to access the IQOS website store5 and receive customer support services, a map of retail locations and a product catalogue. Members receive regular email invitations to complete surveys with opportunities to win prizes. Conclusions These promotion activities have undoubtedly made substantial numbers of Ontarians aware of IQOS. Yet, the government has not provided guidance as to absolute and relative potential harms. Our observations of tactics to promote a new tobacco product in a dark market may inform government regulatory policy and non-governmental organisation efforts wherever heat-not-burn products are introduced.

1 February 2019 in American Journal of Public Health
Verified
Journal Article
Closed access
AMAnnalise Mathers
Annalise Mathers
BHBen Hawkins
Ben Hawkins
KLKelley Lee
Kelley Lee
While the public health community has focused on the harm-reduction potential of new nicotine delivery systems (NNDSs) and, conversely, their potential for impeding overall efforts to prevent and reduce tobacco use, limited analysis has been conducted on the role of leading transnational tobacco companies (TTCs) in this rapidly growing market. Following aborted efforts during the 1980s and 1990s to develop reduced-risk products, TTCs have heavily invested in selected NNDS products since 2010 via acquisitions and internal research and development. This article catalogs and analyzes the patterns of investment in NNDSs by leading TTCs over time, and identifies differences in the companies’ approaches to NNDS product acquisition and development in specific markets globally. This analysis raises important questions regarding the companies’ intent, which appears to be to sustain, rather than replace, cigarette sales, and to increase their influence and credibility with respect to NNDS policy and regulation. We identify the need for greater public health vigilance and research to understand and respond to the increasingly significant role of NNDSs in TTCs’ global business strategies, to ensure that NNDSs advance, rather than hinder, tobacco control efforts.